Published on 22/06/2012
New breast cancer drug stalls HER2+ disease by an average 6 months compared to the current standard of care.
Pertuzumab, marketed as Perjeta by Swiss drug maker Roche, is a targeted medicine that targets a protein found in HER2-positive breast cancers.
New data from a late-stage study has shown that combining Pertuzumab with another combination of drugs significantly improved the overall progression free survival of patients with HER2-positive breast cancer.
An international Phase III trial was carried out by researchers on 808 people. Patients given Herceptin, chemotherapy and a placebo lived progression-free for an average of 12.4 months.
In contrast patients given Herceptin, chemotherapy and Perjeta lived an additional 6.1 months to an average of 18.5 without their disease getting worse, known as Progression Free Survival.
Roche have also recently confirmed that Perjeta has demonstrated a significant overall survival benefit compared to the current standard of care, Herceptin and chemotherapy. These full data will be presented at a medical conference later in 2012.
Perjeta was granted approval by U.S. health regulators earlier this month.
Roche is hoping that it will become the standard treatment for women with HER-2 positive cancer, which makes up about a quarter of all breast cancers and has no cure.
If Perjeta becomes licensed in the UK, patients with health insurance will have access to the drug on their policy before it becomes approved on the NHS.
© ActiveQuote Ltd. 2012Categories: Medical